Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
2011 · Blood Cancer Journal · 106 citations
https://doi.org/10.1038/bcj.2011.43
J
Jianbiao Zhou
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
149
Papers
4.5K
Citations
37
h-index
65
i10-index
Jianbiao Zhou is an academic researcher from National University of Singapore. The author has contributed to research in topics: Protein Degradation and Inhibitors & Multiple Myeloma Research and Treatments & Acute Myeloid Leukemia Research. The author has an h-index of 37, co-authored 127 publications.
ORCID: 0000-0002-5679-671XPapers by this author
worksSuper-enhancers: critical roles and therapeutic targets in hematologic malignancies
2019 · Journal of Hematology & Oncology · 104 citations
https://doi.org/10.1186/s13045-019-0757-y
Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma
2021 · Cellular and Molecular Life Sciences · 78 citations
https://doi.org/10.1007/s00018-021-03756-3
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside
2009 · Journal of Hematology & Oncology · 66 citations
https://doi.org/10.1186/1756-8722-2-33
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
2019 · Nature Communications · 48 citations
https://doi.org/10.1038/s41467-019-10127-x
A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase
2018 · Journal of Hematology & Oncology · 38 citations
https://doi.org/10.1186/s13045-018-0581-9
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat